Page 129 - 《中国药房》2024年10期

4 结语 34（5）：595-599.
艾滋病合并肿瘤患者并发症多，基础情况较差，用 CHEN Y B，WAN N，WANG B，et al. Case analysis of a
药复杂，治疗期间可能存在机会性感染、药物相关不良 patient with osimertinib-induced interstitial pneumonia
who re-used EGFR-TKI therapy[J]. China Pharm，2023，
反应、药物相互作用等情况。临床药师在协助医师诊疗
34（5）：595-599.
的过程中，通过分析患者疾病与药物的相关性、机会性
[10] CHEN W Y，ZHANG L J，SHEN H，et al. Successful
感染的可能病原菌、静脉血栓风险等问题，梳理各种药
administration of low-dose almonertinib in a patient with
物用药的必要性及安全性，开展全程药学服务，充分发
lung adenocarcinoma after osimertinib-induced interstitial
挥了临床药师在合理用药、药物及其剂量调整、药物不 lung disease：a case report and literature review[J]. Anti‐
良事件监测、风险评估、治疗药物监测等方面的重要作 cancer Drugs，2023，34（3）：460-466.
用，为患者提供了个体化的药学服务。 [11] DAI H P，MA F，REN Y H，et al. Expert consensus on the
参考文献 diagnosis and treatment of anticancer drug-induced inter‐
[ 1 ] Acquired Immunodeficiency Syndrome and Hepatitis C stitial lung disease[J]. Curr Med Sci，2023，43（1）：1-12.
Professional Group，Society of Infectious Diseases， [12] SHENDEROV K，COLLINS S L，POWELL J D，et al.
Chinese Medical Association，Chinese Center for Disease Immune dysregulation as a driver of idiopathic pulmonary
Control and Prevention. Chinese guidelines for diagnosis fibrosis[J]. J Clin Invest，2021，131（2）：e143226.
and treatment of human immunodeficiency virus infection/ [13] DUCHEMANN B，DIDIER M，PAILLER M C，et al. Can
acquired immunodeficiency syndrome：2021 edition[J]. Med nivolumab be used safely in idiopathic pulmonary fibrosis?
J Peking Union Med Coll Hosp，2022，13（2）：203-226. [J]. Rev Mal Respir，2019，36（2）：209-213.
[ 2 ] RECONDO G，FACCHINETTI F，OLAUSSEN K A，et [14] 中华医学会热带病与寄生虫学分会艾滋病学组. 艾滋病
al. Making the first move in EGFR-driven or ALK-driven 合并侵袭性真菌病诊治专家共识[J]. 中华临床感染病杂
NSCLC：first-generation or next-generation TKI?[J]. Nat 志，2019，12（4）：253-267.
Rev Clin Oncol，2018，15（11）：694-708. AIDS Division of Tropical Diseases and Parasites Branch
[ 3 ] OHMORI T，YAMAOKA T，ANDO K，et al. Molecular of Chinese Medical Association. Expert consensus on diag-
and clinical features of EGFR-TKI-associated lung injury nosis and treatment of HIV infection combined with
[J]. Int J Mol Sci，2021，22（2）：792. invasive fungal diseases[J]. Chin J Clin Infect Dis，2019，
[ 4 ] JOHKOH T，LEE K S，NISHINO M，et al. Chest CT diag‐ 12（4）：253-267.
nosis and clinical management of drug-related pneumoni‐ [15] TAKESUE Y，HANAI Y，ODA K，et al. Clinical practice
tis in patients receiving molecular targeting agents and guideline for the therapeutic drug monitoring of vorico-
immune checkpoint inhibitors：a position paper from the nazole in non-Asian and Asian adult patients：consensus
Fleischner Society[J]. Chest，2021，159（3）：1107-1125. review by the Japanese Society of Chemotherapy and the
[ 5 ] CHENG Y，HE Y，LI W，et al. Osimertinib versus com‐ Japanese Society of Therapeutic Drug Monitoring[J]. Clin
parator EGFR TKI as first-line treatment for EGFR- Ther，2022，44（12）：1604-1623.
mutated advanced NSCLC：FLAURA China，a rando- [16] ABOUREHAB M A S，ALQAHTANI A M，YOUSSIF B
mized study[J]. Target Oncol，2021，16（2）：165-176. G M，et al. Globally approved EGFR inhibitors：insights
[ 6 ] YIN Y C，SHU Y M，ZHU J R，et al. A real-world pharma‐ into their syntheses，target kinases，biological activities，
covigilance study of FDA Adverse Event Reporting System receptor interactions，and metabolism[J]. Molecules，2021，
（FAERS）events for osimertinib[J]. Sci Rep，2022，12（1）： 26（21）：6677.
19555. [17] 徐蕾，张伟霞，许倍铭，等. 那屈肝素临床应用药学专家
[ 7 ] LU S，DONG X R，JIAN H，et al. AENEAS：a rando- 意见[J]. 上海医药，2022，43（21）：12-17.
mized phase Ⅲ trial of aumolertinib versus gefitinib as XU L，ZHANG W X，XU B M，et al. Opinions of pharma‐
first-line therapy for locally advanced or metastatic non- ceutical experts on clinical application of nadroparin[J].
small-cell lung cancer with EGFR exon 19 deletion or Shanghai Med Pharm J，2022，43（21）：12-17.
L858R mutations[J]. J Clin Oncol，2022，40（27）：3162- [18] 质子泵抑制剂预防性应用专家共识写作组. 质子泵抑制
3171. 剂预防性应用专家共识：2018[J]. 中国医师杂志，2018，
[ 8 ] LU S，WANG Q M，ZHANG G J，et al. Efficacy of 20（12）：1775-1781.
aumolertinib（HS-10296）in patients with advanced EGFR Expert Consensus Writing Group on the Prophylactic
T790M+ NSCLC：updated post-national medical products Application of Proton Pump Inhibitors. Expert consensus
administration approval results from the APOLLO regi- on the preventive application of proton pump inhibitors：
strational trial[J]. J Thorac Oncol，2022，17（3）：411-422. 2018[J]. J Chin Physician，2018，20（12）：1775-1781.
[ 9 ] 陈永邦，万宁，王冰，等 . 1 例奥希替尼致间质性肺炎患 （收稿日期：2023-12-20 修回日期：2024-04-18）
者再用EGFR-TKI治疗的病例分析[J]. 中国药房，2023， （编辑：孙 冰）

中国药房 2024年第35卷第10期 China Pharmacy 2024 Vol. 35 No. 10 · 1275 ·